Biotechnology Company

Adimab

0%

Funding Goal
Funding Raised So Far $39,682,384
Funding Commitments $0
Funding Remaining
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Company Overview


Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

lock icon

Invest in Company

Sign up or log in now to unlock profile details and access financials, company documents, and invest in companies.

Business Summary


Company Age
Employees
Sub-Industry
Prior Year Revenue
Current Year Revenue
Next Year Revenue

Management


Tillman Gerngross
Chief Executive Officer
Tillman G......

Tillman U. G...... is the Co - Founder & CEO of Adimab.


- Co-Founder, Chairman, Arsanis Inc.

- Co-founder and CSO, GlycoFi Inc. (acquired by Merck 2006)

- Professor of Bioengineering, Dartmouth College

- Venture Partner, SV Life Sciences

Guy Van Meter
Vice President Business Development
Guy V......

Guy V...... is the Vice President & Head of Business Development at Adimab.

- Business Development and Strategic Alliances, Pfizer Inc.

- Business Development, Technology Licensing, Dyax Corp.

- F.W. Olin Graduate School of Management at Babson

Errik B. Anderson
Chief Operating Officer
Errik B......


Errik B...... is the Co - Founder & Chief Operating Officer at Adimab.


Robert Mabry
Director Engineering
Robert M......

Robert M...... is the Associate Director, Antibody Discovery & Bispecific Engineering at Adimab.

-Senior Scientist, Head of Phage Display, ZymoGenetics Inc.

-Scientist, ImClone Systems Inc.

Max Vasquez
Vice President
Max V......

Max V...... is the Vice President & Head of Computational Biology at Adimab.

- Senior Director, Research, PDL BioPharma

- Bocaraca Consulting, Founder & President

Eric Krauland
Director
Eric K......

Eric K...... is the Director, Antibody Discovery & Optimization at Adimab.

- Massachusetts Institute of Technology

Piotr Bobrowicz
Director
Piotr B......

Piotr B...... is the Director, Open Innovation at Adimab.

- Group Leader, High Throughput Strain Screening, Merck & Co. Inc.

- Senior Scientist, Strain Development, GlycoFi Inc.

Carl L. Gordon
Director
Carl L......

Dr. is a founding General Partner of OrbiMed and Co-Head of Private Equity. Dr. is active in both private equity and small-capitalization public equity investments.

He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997.

He was a Fellow at The Rockefeller University from 1993 to 1995. Dr.

received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a Bachelors degree from Harvard College.

Bill Maris
Director
Bill M......

Bill M...... is the Board Director at Adimab.


Bill is the Managing Partner of Google Ventures, and brings with him a combination of technical expertise and hands on start-up experience, including founding Web hosting pioneer Burlee.com (now part of Web.com), where he built much of the key computing, network and technological infrastructure.

Prior to that, Bill was a biotechnology and healthcare portfolio manager for Stockholm, Sweden-based Investor AB. Bills background also includes research at the Duke University Medical Center, Department of Neurobiology.

Bill received his degree in Neuroscience with honors from Middlebury College, and is based in Mountain View, CA.

Michael Ross
Director
Michael R......

Dr. Michael R...... joined SVLS as a Venture Partner in 2001, became a Managing Partner in 2002 and is based in San Francisco.

Michael serves on the boards of Adimab, Arsanis Link Medicine, NKT Therapeutics, Rempex and Sutro Biopharmaceuticals. Michael also serves on the Thayer School of Engineering (Dartmouth College). He has also served on the boards of Aderis Pharmaceuticals, Alinea, Archemix, Arris Pharmaceutical, Carta Proteomics, CyThera, Glycofi, Epimmune, Genencor, Ikano, Itero Bio pharmaceuticals, MetaXen, Mpex, Rinat and Xenova.

Michael was the tenth employee at Genentech where he worked for 13 years. He served as Genentech team leader for Humulin (human insulin-Lilly), Roferon(Interferon alpha -Roche), Protropin (hGH), Vice President of Development during the development of Activase, Nutropin and Pulmozyme.

Michael then started Genentech's protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry.

Terry McGuire
Director
Terry M......

Terry M...... is a co-founder and managing general partner of Polaris Venture Partners based in the Boston office. Terry focuses on life sciences investments.

Experience:
Prior to starting Polaris, Terry spent seven years at Burr, Egan, Deleage & Co. investing in early stage medical and information technology companies. Terry began his career in venture capital at Golder, Thoma and Cressey in Chicago.

Boards:
Terry has co-founded three companies: Inspire Pharmaceuticals, AIR (Advanced Inhalation Research, Inc.), and MicroCHIPS.

Terry represents Polaris on the boards of directors of Acceleron Pharma, AdiMAB, Arsenal Medical Incl, Ironwood Pharmaceuticals,Life Line Screening, MicroCHIPS, Inc., Pulmatrix Inc., Tempo Pharmaceuticals and Trevena, Inc.

He has also served on the boards of Akamai, Aspect Medical Systems, Cubist Pharmaceuticals, deCODE Genetics (DCGN), GlycoFi, Transform Pharmaceuticals, and Remon Medical Technologies.

Terrance G. McGuire
Director
Terrance G......

Terry is a co-founder and general partner of Polaris Venture Partners based in the Boston office. Mr. focuses on life sciences investments.

Prior to starting Polaris, Mr. spent seven years at Burr, Egan, Deleage & Co. investing in early-stage medical and information technology companies. Mr. has co-founded three companies: Inspire Pharmaceuticals, AIR (Advanced Inhalation Research, Inc.) and MicroCHIPS.

Mr. represents Polaris on the boards of directors of Acceleron Pharma, Adimab, Arsenal Medical, deCODE Genetics, Ironwood Pharmaceuticals, Life Line Screening, MicroCHIPS, Pulmatrix, SustainX Energy Storage Solutions and Trevena.

He has also served on the boards of Akamai, Aspect Medical Systems, Cubist Pharmaceuticals, GlycoFi, Transform Pharmaceuticals and Remon Medical Technologies. Mr. is chairman emeritus of the National Venture Capital Association.

K. Dane Wittrup
K. D......

K. D...... is the Co - Founder, Office of the CSO & Chairman of the SAB at Adimab.

- Co - Founder, BioDisplay Technologies (acquired by Abbott Laboratories 2001)

- Professor of Chemical Engineering and Bioengineering, Massachusetts Institute of Technology

Philip Chase
Philip C......

Philip C...... is the General Counsel at Adimab.

-General Counsel, Alnylam Pharmaceuticals Inc.

-General Counsel, Epix Pharmaceuticals Inc.

-Chief Corporate Counsel, Transkaryotic Therapies Inc. (TKT)

0%

Funding Goal
Funding Raised So Far $39,682,384
Funding Commitments $0
Funding Remaining
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Documents


Contact


Adimab

Lebanon, NH 03756, US

Top 10 Tips for Entrepreneurs Seeking Funding

Users who follow these tips increase their fundraising odds substantially.

  • Complete Your Funding Profile
    • Complete your funding profile with all sections filled, including your products and services, a complete management team with headshots, and slideshow with product images.
  • Complete a Business Plan (Optional)
    • Complete a Business Plan in EquityNet and refine your financial projections using the benchmarking alerts in the Business Plan Analysis report.
  • Upload Important Investment Documents
    • Upload and present any other important investment documents such as pitch decks, financial statements, and offering materials.
  • Use EquityNet Crowdcast
    • Use the EquityNet Crowdcast system to automatically email invitations to your contacts in order to build additional exposure for your company.
  • Construct Concise Introductory Messages
    • Construct and send a concise introductory message to investors, including primary reasons why they should want to invest such as KPIs, expected returns, and forecasted revenue.
  • Be Proactive in Messaging Investors
    • Be proactive in messaging many investors and include a simple way for them to connect with you for a web meeting or call, such as a Calendly link.
  • Use the Activity System
    • Use the Activity system to track interested investors, and send prompt follow-up messages to investors who viewed your profile or showed interest.
  • Prepare for Due Diligence
    • Prepare for due diligence questions by interested investors and use your Business Plan and investment documents to satisfy such requests.
  • Keep Your Funding Profile Updated
    • Keep your funding profile updated with new funding raised/committed and message interested investors with any new milestones achieved.
  • Do Not Respond to Unknown Investors
    • Do not respond to or engage any parties outside of EquityNet that are not listed as approved investors (this may happen due to your public profile and LinkedIn connections).